The neuro®bromatoses are autosomal dominant diseases that have widespread effects on ectodermal and mesodermal tissue. The commonest member of the group is neuro®bromato-sis type 1 (NF1) which varies in severity but which can affect all physiological systems. Neuro®bromas are the characteristic lesions of the condition and not only occur in the neuraxis but may also be found in the oropharnyx and larynx; these may produce dif®culties with laryngoscopy and tracheal intubation. Pulmonary pathology includes pulmonary ®brosis and cystic lung disease. The cardiovascular manifestations of NF1 include hypertension, which may be associated with phaeochromocytoma or renal artery stenosis. Neuro®bromas may also affect the gastrointestinal tract and carcinoid tumours may be found in the duodenum. This review documents the aetiology and clinical manifestations of the neuro®bromatoses and discusses their relevance to the anaesthetist. 
Diagnostic features of NF1
Despite major advances in the molecular genetics of NF1, diagnosis remains largely based on clinical criteria (Table 1) . 35 Cafe Â-au-lait spots are symmetrical¯at areas of skin hyperpigmentation with rounded edges and are seen in newborns with NF1; their number and size increase during infancy. By adulthood, about 95% of NF1 patients have cafe Â-au-lait spots. Their presence suggests NF1 although familial cafe-au-lait spots do occur rarely. In addition, 70% show freckling of the intertriginous area of the axilla or groin. 45 Neuro®bromas are the major feature of NF1 and fall into three clinically and histologically distinct types. 109 Cutaneous neuro®bromas occur in more than 95% of patients, and are discrete, benign tumours found within the dermis. Nodular neuro®bromas arise in peripheral nerves and may be found at any site; despite their size, they do not in®ltrate surrounding tissues. Paraspinal neuro®bromas may grow to an enormous size, giving rise to the classic thoracic dumbbell' tumour ( Fig. 1) .
Plexiform neuro®bromas are the hallmark lesion of NF1. These occur in 30% of NF1 patients, are usually congenital, and affect long portions of the nerve involved; in®ltration of the nerve itself and the surrounding tissue may occur, giving rise to extensive dis®guration. It is thought that John Merrick, the Elephant Man, may have suffered from plexiform neuro®bromatosis 108 although proteus now appears to be a more likely diagnosis. 100 Apart from the obvious mechanical complications of such tumours, plexiform neuro®bromas have a tendency, albeit rare, to undergo malignant change forming malignant peripheral nerve sheath tumours. Malignant progression occurs in 2±16% of patients and is the major cause of morbidity and mortality in NF1. 51 Pilocytic astrocytomas are a benign form of astrocytoma, and when arising from the optic nerve or chiasm, are termed optic gliomas. They are seen in 15% of NF1 patients on MRI and are symptomatic in 2±5%; they are slow growing and generally do not undergo malignant change. 57 About 95% of individuals with NF1 will develop Lisch nodulesÐbenign multiple melanotic hamartomas of the iris. 46 Finally, distinctive bony lesions including dysplasia of the sphenoid wing and thinning of long bones contribute to the diagnostic criteria of NF1. 28 
Other tumours found in NF1
In addition to the neuro®bromas that characterize the disease, other tumours occur more commonly in NF1. Phaeochromocytoma occurs more commonly in NF1 patients than in the general population. 58 Although the features of some of the multiple endocrine neoplasia syndromes overlap with NF1 (e.g. neural crest origin tumours), no association between the two conditions has been established. 41 Intestinal tumours are commonly seen in NF1 patients and interestingly have a predilection for the duodenum and especially the ampulla of Vater. 50 Malignant gliomas are found in approximately 2% of patients with NF1. 102 Finally, the association of juvenile chronic myeloid leukaemia with NF1 has helped in the identi®cation of the role of the NF1 gene as a tumour suppressive gene. 7 
Additional features of NF1
Patients with NF1 often demonstrate relative macrocephaly and tend to be, on average, shorter in stature. Pituitary abnormalities include growth hormone de®ciency and central precocious puberty which may occur in the absence of optic chiasm gliomas; 12 radiotherapy treatment of the latter may increase the risk of growth retardation and intellectual de®cits.
1 Learning disabilities occur in 50% of patients. However, the relationship between lower range IQ and the presence of so called`unidenti®ed bright objects' seen in the basal ganglia, thalamus and brainstem on T 2 weighted MRI imaging in 70% of patients remains controversial. 73 Mental retardation (full scale IQ less than 70) is only slightly more frequent than that of the general population. While some social handicap might be expected in severely affected sufferers, no uniform psychiatric syndrome is encountered. 67 Other conditions which occur more commonly in the NF1 population include epilepsy, 53 headaches, 80 aqueduct stenosis 90 and hydrocephalus. Although the incidence of vestibular schwannoma is probably no greater than that of the general population, deafness is common. 16 Delayed central conduction times of auditory brain stem evoked potentials have been observed 76 and conductive hearing loss may be the consequence of bony deformity or tumour within the auditory meatus. 
NF: clinical presentations and anaesthetic implications
Neuro®bromatosis type 2 (bilateral acoustic neuro®bromatosis, central neuro®bromatosis)
The recognition of a group of patients with familial tendency to pass on bilateral acoustic neuromas (vestibular schwannomas) coupled with genetic studies has resulted in the recognition of NF2 as a distinct entity; 49 this division in the neuro®bromatoses is important both in the management and genetic counselling of patients.
Genetics and pathophysiology of NF2
The birth incidence of NF2 lies between 1 in 33 000±40 000 with a prevalence within the population of 1 in 210 000. 44 It is inherited in an autosomal dominant fashion; however, in common with NF1, 50% of cases represent sporadic gene mutations. 27 Using genetic analysis of large pedigrees, the NF2 gene has been shown to reside on chromosome 22q 12.1 and the gene has recently been cloned. It spans 110 kb of genomic DNA and encodes a cytoskeletal protein known as merlin or schwannomin. 20 It appears that the NF2 gene acts as a tumour suppressor, both in NF2, sporadic meningiomatosis and other neuroectodermal tumours. 19 Although there appears to be some correlation between genotype and phenotype, there are exceptions. Limited gene analysis is now available and may be useful for genetic counselling.
Diagnostic features of NF2
As with NF1, diagnosis depends largely on the recognition of clinical features (Table 2) . 35 The de®ning feature of NF2 is the presence of bilateral vestibular schwannomasÐtumours arising from the vestibular branch of the VIII cranial nerve (Fig. 2) .
Patients typically present with a gradual, progressive and often asymmetrical hearing loss although sudden hearing loss may occur. The mean age of onset of symptoms is 24 yr whilst non-NF patients with sporadic tumours present in their mid-forties. 26 Whilst the occurrence of bilateral vestibular schwannomas con®rms NF2, the presence of a unilateral vestibular schwannoma in conjunction with other NF2 associated features should raise the possibility of NF2.
These features result from abnormal growth in certain cell types and include meningiomas ( Fig. 3 ), other schwannomas, gliomas and juvenile posterior subcapsular lenticular opacities and cortical cataracts. Although neuro®bromas can occur, plexiform morphology is not seen in NF2. A nonspeci®c ®nding in NF2 is intracerebral calci®cation.
Segmental neuro®bromatosis
Both NF1 and NF2 can present as a non-generalized form in which only one body part is affected. This so-called segmental neuro®bromatosis' appears to represent somatic mosaicism in which only some cells possess the NF1 or NF2 gene mutation. Depending on the segment affected, the risk to offspring may be very much lower than the 50% risk for generalized disease. Other`incomplete' forms of neuro®-bromatosis may involve balanced translocations, and may be familial with dominant inheritance patterns. A wide variety of clinical pictures has therefore been described and classi®ed.
Anaesthetic considerations of neuro®bromatosis
Because of the relative rarity and the only relatively recent recognition of NF2 as a distinct entity, most of the literature concerning the medical and anaesthetic complications of neuro®bromatosis relates to NF1. As the neuro®bromatoses affect both ectodermal and mesodermal tissue, it is unsurprising that all systems of the body may be involved (Table 3) .
Airway
An estimated 5% of patients with NF1 have an intra-oral manifestation of the disease. 5 Discrete neuro®bromas may 93 94 or the larynx. 10 30 When the latter is involved it is often the aryepiglottic fold or arytenoids that are affected, presumably re¯ecting those areas most rich in terminal nerve plexuses. 47 Unilateral vocal cord palsy has been reported secondary to involvement of the recurrent laryngeal nerve. 79 Discrete and plexiform neuro®bromas commonly occur in the cervical region and large tumours of the parapharyngeal space may result in distortion of the airway. Pathologies in NF1 that affect the tongue, larynx and cervical tissues may cause obstruction, and symptoms of dyspnoea, stridor, loss or change of voice or dysphagia should warn the anaesthetist of potential airway problems. Suspicion warrants specialist examination with indirect laryngoscopy and CT or MR imaging.
Airway obstruction after induction of anaesthesia has been reported in patients with a tongue neuro®broma 14 and a neuro®broma involving the laryngeal inlet. 78 Both patients required emergency tracheostomy. Even if intra-oral pathology is recognized pre-operatively, elective awake ®breop-tic tracheal intubation may fail because of a grossly distorted anatomy. 113 However, successful intubation after inhalation anaesthesia with sevo¯urane has been described. 107 In addition, the presence of macroglossia, macrocephaly, speci®c mandibular abnormalities 54 and cervical spine involvement may contribute to dif®culties of airway management. Painless dislocation of cervical vertebrae has been reported in a patient with multiple cervical neuro®broma and it has been suggested that radiographic examination of the neck should be performed before anaesthesia in these patients in order to avoid spinal cord damage during laryngoscopy and tracheal intubation. 59 
Respiratory system
Neuro®bromatosis may affect the conducting airways, lung parenchyma, the thoracic cage and the chest wall.
Conducting airways
Mediastinal neuro®bromas usually originate in the posterior mediastinum or spread from the retroperitoneal space or cervical paraspinal areas. Tracheal and bronchial compression with rapidly progressive symptoms may occur 74 and may present a dif®cult challenge to the anaesthetist. 21 Lung parenchyma Intrapulmonary neuro®bromas are rare, usually asymptomatic and carry a good prognosis. However, they may grow to a large size resulting in cough and dyspnoea. Excision of such tumours is advocated as they carry a risk of malignancy. 96 The association of pulmonary ®brosis and NF1 has long been recognized although estimates of its incidence of 10±20% 17 have probably been overstated. More recent surveys 45 have suggested that the association may even be coincidental. However, reports suggest that the typically bilateral upper lobe pulmonary ®brosis is of adult onset and is progressive, 9 87 and the resulting restrictive defect may culminate in pulmonary hypertension and right ventricular failure. 97 In addition, cystic lung disease may co-exist 63 as a honeycomb lung structure or large apical cysts. 65 Although rare, pneumothorax has been reported. 101 Chest wall deformities Thoracic spinal curvatures are common in NF1 and affect approximately 10% of NF1 patients. They appear early in childhood and often require corrective surgery. 2 Dystrophic spinal curvatures are short and sharp and progress throughout life. Severe kyphosis, although uncommon, may be associated with tumours and a high risk of neurological de®cit. Scoliosis with rotation may also occur and produces a reduction in lung volume, which if severe, may result in respiratory failure. Although pectus excavatum and carinatum occur in up to 30% of patients with NF1, 81 they do not contribute to respiratory problems. Neuro®bromas and schwannomas may produce erosion of the ribs and are a rare cause of¯ail chest. 40 It is clear that evaluation of the respiratory system is an essential part of the pre-operative management of patients with NF1, and as well as chest x-ray, may include CT evaluation of the thorax and detailed lung function testing.
Cardiovascular system
Although hypertension is the most commonly occurring cardiovascular manifestation of NF, the disease may also primarily affect the myocardium and the vasculature.
Hypertension
Hypertension occurs in approximately 6% of NF1 patients and may be multifactorial. In the majority of cases, essential hypertension coincidentally coexists with the condition; however, in 30% of cases the hypertension is secondary to renovascular disease, 43 aortic coarctation or phaeochromocytoma.
Hypertension presenting in the young NF1 sufferer is usually because of renal artery stenosis, which may be bilateral. 8 The arterial lesions are of variable morphology with fusiform intimal narrowing, or nodule or aneurysm formation. 88 Surgery to stenosed vessels may be disappointing, possibly as the vessel abnormalities extend to intrarenal tissue. However, success has been reported with percutaneous angioplasty, resulting in remission of hypertension. 32 Regular arterial pressure measurement is thus a vital screen in even young patients with NF1 and mandatory in the pre-operative assessment of these patients. Caution should be taken when treating hypertension with potentially renotoxic drugs.
A recent review of the literature suggests that phaeochromocytoma affects between 0.1±5.7% of patients with NF1 but almost 25% of patients with phaeochromocytoma have the disease. 64 The mean age of presentation in NF1 patients is 42 yr and most patients have solitary, nonmalignant tumours. The tumours are more commonly seen in association with other neurocutaneous syndromes such as the Von Hippel-Lindau syndrome. 72 Sudden, short-lasting frontal or occipital headache occurs in 60% of patients while other common symptoms include anxiety attacks, weight loss, palpitations and night sweats. 84 Sustained or paradoxical hypertension that proves resistant to treatment should raise the suspicion of phaeochromocytoma and appropriate investigations such as urinary catecholamine estimation and abdominal CT scanning should be performed. It is vital to exclude phaeochromocytoma as a cause of hypertension as anaesthesia, surgery and pregnancy are particularly hazardous if it is undiagnosed pre-operatively. Death during orthopaedic surgery as a result of phaeochromocytoma has been reported in NF1 patients. 28 48 The subject of anaesthesia for the patient with phaeochromocytoma has been recently reviewed. 75 Coarctation of the thoracic 22 or abdominal 110 aorta is a rare cause of hypertension in the NF1 patient.
Vasculopathy and cardiac pathology
In addition to the renal arterial lesions, in some cases of NF1 a generalized vasculopathy exists. Micronodular vascular proliferation may be seen in the nervous system and visceral organs: when a prominent feature, this is termed vascular neuro®bromatosis. In spite of varying histological appearances, it has been proposed that the primary mechanism is that of schwann cell proliferation with secondary degeneration or ®brosis of the vessel wall. This process may result in formation of both aortic and cerebral aneurysms. 85 Although initial studies suggested congenital heart defects were more common in the NF1 population, 71 a subsequent review 56 found no clear evidence of a link. Idiopathic hypertrophic cardiomyopathy has been reported in NF1 25 86 but doubt exists as to whether this is a coincidental ®nding in two conditions that have a similar incidence. Fitzpatrick 31 suggests that the left ventricular hypertrophy may be secondary to neuro®bromatosis and because of the abnormal metabolism of catecholamines or nerve growth factor, or that both diseases represent defects of neural crest tissue. In addition, neuro®bromas may involve the heart causing both hypertrophy and out¯ow obstruction; 77 the development of an endocardial ®bromus-cular band giving rise to right ventricular failure has also been described. 83 The presence of coronary artery aneurysms has been documented 15 and may represent a vascular manifestation of the disease; coronary vasospasm has been associated with sudden death in such a patient. 38 Superior vena caval obstruction resulting from large mediastinal tumours is well recognized in NF1 74 and vascular lesions involving the subclavian artery may result in life-threatening haemothorax. 66 99 A high index of suspicion is required to diagnose the involvement of mediastinal structures and radiological examinations may need repeating at frequent intervals to exclude signi®cant intrathoracic tumours.
The autonomic nervous system is not immune to the condition and sudden death has been reported in a patient with neuro®bromatosis who was found to have a neuro®-broma of the vagus nerve. 11 It is clear that careful questioning concerning cardiovascular disease coupled with appropriate investigations is an integral part of the assessment of the patient with neuro®bromatosis.
Central nervous system
As tumours of the central nervous system account for the major portion of the morbidity and mortality of patients with neuro®bromatosis, it is unsurprising that patients often present for cranial or spinal neurosurgery. Anaesthesia for such patients follows normal neuroanaesthetic practice although surgery to plexiform neuro®bromas may result in severe haemorrhage.
Anaesthetic assessment of such patients should take into account the increased incidence of epilepsy, learning dif®culties and the possibility of undiagnosed CNS tumours.
Clinicians should be open to the possibility of multiple lesions and not necessarily attribute new symptoms to a preexisting tumour. Fatal neurogenic pulmonary oedema has been reported in a child with NF1 with unsuspected cerebral involvement when undergoing spinal surgery. 103 Although an uncommon manifestation of NF1, cerebrovascular disease has been reported and probably represents similar pathology of vascular structures as described earlier.
The most common disorder is a progressive narrowing of the internal carotid artery at the origin of the anterior and middle cerebral arteries. 95 Although it is not clear that there is an increase in the incidence of cerebrovascular accident in NF1 patients once the risk factor of hypertension is excluded, symptomatic ischaemic disease has been reported and con®rmed by cerebral angiography. Furthermore, cerebral aneurysm formation has been reported and affects both the anterior and posterior circulations. 89 Control of arterial pressure perioperatively must be carefully considered in the light of arterial occlusive disease and the potential presence of aneurysms.
In addition to the respiratory pathology described above, involvement of brainstem structures by neuro®broma or glioma may result in central hypoventilation syndromes which may require respiratory support even in childhood. 91 Such patients may exhibit protracted weaning from mechanical ventilation post-operatively.
Gastrointestinal and genitourinary systems
Gastrointestinal tumours in NF1 may present with disordered gut motility, abdominal pain, haematemesis or melaena; although neuro®bromas, usually affecting the jejenum or stomach, are the most common lesions, leiomyoma, ganglioneuroma and sarcoma have been described. All may result in intestinal perforation.
Gastrointestinal symptoms may be the ®rst manifestation of neuro®bromatosis. 33 Carcinoid tumours have been described in NF1 and authors agree that the association is not coincidental. Fernandez 29 has suggested that neuro®bromas and carcinoid tumours in NF1 have a common neuroendocrine origin, and this is supported by a case in which an intestinal neuro®broma showed histological transition into a carcinoid tumour. 4 An unusual feature of the carcinoid tumour occurring in NF1 is the predilection for the duodenum and especially the ampulla of vaterÐan uncommon site in the non-NF1 population. 18 Patients may present with jaundice or upper gastrointestinal haemorrhage or obstruction; often, by the time a diagnosis is reached, metastases are present in the liver. The subsequent release of vasoactive peptides may result in patients presenting with the carcinoid syndrome of ushing, diarrhoea, bronchoconstriction and right heart lesions. Anaesthesia and surgery may be hazardous in this situation. Perioperative management of patients with carcinoid syndrome has been comprehensively reported by Veall. 104 It is important to note that carcinoid tumours and phaeochromocytoma may co-exist and, therefore, patients with phaeochromocytoma require imaging of the duodenum to exclude pathology in this region. 111 The genitourinary tract may be involved in NF1 and retroperitoneal neuro®bromas may result in ureteric obstruction and hydronephrosis. Similarly, bladder out¯ow obstruction has been reported 92 and bladder catheterization may be dif®cult.
Pregnancy
Although neuro®bromatosis appears to have no intrinsic effect on fertility, a high rate of spontaneous abortion and stillbirth has been reported. 24 112 There is little documentation of dif®cult or obstructed labour because of uterine or vaginal neuro®broma but pre-term labour may occur in up to 30% of patients. 36 Pregnancy is often associated with an increase in the number and size of dermal neuro®bromas and the potential for rapid increase in the size of CNS tumours must be considered.
Hypertension occurs commonly in pregnant NF1 sufferers 98 and arterial pressure must be carefully monitored throughout pregnancy. Both phaeochromocytoma and renal artery stenosis may present during pregnancy, perhaps with a lethal outcome. 42 Furthermore, renal artery stenosis may be induced by pregnancy when it may be associated with the haemolysis, elevated liver enzymes and low platelets (HELPP) syndrome. 37 Anaesthesia for the pregnant patient with neuro®broma-tosis is not well documented. In the majority of patients with mild disease, the question of regional versus general anaesthesia is the same as that for patients without neuro®bromatosis. In those patients with more extensive disease, regional techniques may be more appropriate, especially if airway problems are present. However, regional anaesthesia may be technically dif®cult if spinal neuro®bromas or scoliosis are present. In addition, the presence of raised intracranial pressure must be excluded before regional anaesthesia is considered, even if this requires CT scanning with its radiation risk. 23 Anaesthesia for phaeochromocytoma in pregnancy carries its own particular dif®culties. 39 
Pharmacology
There have been many reports suggesting an increased sensitivity of patients with NF1 to non-depolarizing neuromuscular blocking drugs. 6 61 62 69 70 114 In addition, the sensitivity to succinylcholine has been reported as increased, 61 62 114 decreased 6 or normal. 62 69 However, these reports are marred by a paucity of detail preventing a de®nite diagnosis of neuro®bromatosis to be established; in addition, with the exception of one study, 6 no neuromuscular monitoring was performed. A large retrospective study of patients given succinylcholine and/or a variety of nondepolarizing neuromuscular blocking drugs with neuromuscular monitoring excluded any de®nite abnormal response to the relaxants given. 82 It was concluded that patients with neuro®bromatosis react in a normal fashion to neuromuscular blocking drugs. However, patients with neuro®bro-matosis should have neuromuscular transmission monitored when neuromuscular blocking drugs are used. This is especially pertinent in NF1 patients with renal impairment or those on concurrent medication (e.g. anticonvulsant drugs), which may interfere with the normal pharmacokinetics or pharmacodynamics of neuromuscular blocking drugs.
Conclusion
The neuro®bromatoses are a group of conditions that vary in their severity but which have fundamental implications for the anaesthetist, physician and surgeon. NF1 is one of the most common genetically transmitted diseases and anaesthetists with a general practice are likely to encounter patients with the condition. Although the manifestations of NF1 are often mild, there may be associated pathology of direct relevance and importance to the anaesthetic management of patients with the disease. It is therefore important to have a working knowledge of the clinical manifestations of the disease (Table 3) so that a systematic approach to the pre-operative assessment of these patients can result in rational perioperative management. 
